Science & Enterprise subscription

Follow us on Twitter

  • Growth patterns in the U.S. show a concentration of technology development in a few cities, with new policies and i…
    about 9 hours ago
  • Many thanks @SciSeeker ... much appreciated
    about 9 hours ago
  • New post on Science and Enterprise: Report – U.S. Needs Regional Technology Centers #Science #Business
    about 9 hours ago
  • The World Solved the Ozone Problem. It Can Solve Climate Change.
    about 1 day ago
  • A solid majority of Americans now says that climate change affects their communities, a finding that could affect f…
    about 2 days ago

Please share Science & Enterprise

FDA Approves New Epilepsy Drug

Brain wiring illustration

Brain wiring illustration (Courtesy, Human Connectome Project and NIH)

19 February 2016. The U.S. Food and Drug Administration approved a molecular therapy for epilepsy designed to supplement treatments for partial-onset seizures. The drug is brivaracetam, marketed as Briviact by UCB, a pharmaceutical company headquartered in Brussels, Belgium.

Epilepsy is a neurological disorder where nerve cell activity in the brain is disturbed, causing seizures with symptoms ranging from blank stares to tingling sensations to loss of consciousness. Some 150,000 people develop epilepsy each year in the U.S., according to Epilepsy Foundation, with 1 in 26 people developing epilepsy in their lifetimes. Despite advances in medications to control seizures, says the foundation, some 500,000 Americans appear to be resistant to current medications and continue to experience seizures.

Briviact, says UCB, is designed for individuals whose seizures are not adequately controlled by current medications, in this case partial-onset seizures that affect part of the brain and usually last for less than a minute. The drug is a designed molecular compound that binds to a protein in the brain, known as synaptic vesicle protein 2A, associated with transmission activity across neurons. 

FDA’s approval was based in part on results from 3 clinical trials with a total of 1,550 participants, which show statistically reliable reductions over 28 days in the frequency of partial-onset seizures for Briviact taken with other drugs, compared to placebos. The trials also show the most common adverse reactions are drowsiness, dizziness, fatigue, nausea, and vomiting. UCB says Briviact was tested in clinical trials for 8 years with 2,400 participants.

Briviact will be available, says the company, as tablets, an oral solution, and injections in doses of 50 mg, 100 mg, and 200 mg per day. Before sales of the drug can begin, however, the U.S. Drug Enforcement Administration needs to classify Briviact for its abuse or dependency potential, which is expected in the next 90 days. The European Commission approved Briviact for marketing in Europe in January 2016.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.